[HTML][HTML] The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review
L Calzetta, BL Ritondo, MC Zappa… - European …, 2022 - Eur Respiratory Soc
Patients suffering from chronic obstructive pulmonary disease (COPD) clinically manifest
airway mucus hypersecretion as sputum expectoration and cough. Evidence accumulated in …
airway mucus hypersecretion as sputum expectoration and cough. Evidence accumulated in …
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to …
L Calzetta, E Pistocchini, A Chetta… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Therapeutic advances in drug therapy of chronic obstructive pulmonary disease
(COPD) really effective in suppressing the pathological processes underlying the disease …
(COPD) really effective in suppressing the pathological processes underlying the disease …
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of …
L Carzaniga, ID Linney, A Rizzi… - Journal of Medicinal …, 2022 - ACS Publications
The development of molecules embedding two distinct pharmacophores acting as
muscarinic antagonists and β2 agonists (MABAs) promises to be an excellent opportunity to …
muscarinic antagonists and β2 agonists (MABAs) promises to be an excellent opportunity to …
[HTML][HTML] Pathophysiology, therapeutic targets, and future therapeutic alternatives in COPD: Focus on the importance of the cholinergic system
F Gomes, SL Cheng - Biomolecules, 2023 - mdpi.com
Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by
airway limitation and changes in airway structure. It has a high global burden of mortality …
airway limitation and changes in airway structure. It has a high global burden of mortality …
[HTML][HTML] The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
D Singh, J Beier, C Astbury, MG Belvisi… - European …, 2022 - Eur Respiratory Soc
Background Navafenterol (AZD8871) belongs to a new class of bronchodilator, the single-
molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD. This …
molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD. This …
Potential drawbacks of ICS/LABA/LAMA triple fixed-dose combination therapy in the treatment of asthma: a quantitative synthesis of safety profile
P Rogliani, F Cavalli, A Chetta, M Cazzola… - Journal of Asthma and …, 2022 - Taylor & Francis
Introduction Inhaled corticosteroid/long-acting β2-adrenoceptor agonist/long-acting
muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination (FDC) is currently …
muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination (FDC) is currently …
[HTML][HTML] The future of inhalation therapy in chronic obstructive pulmonary disease
M Cazzola, J Ora, L Calzetta, P Rogliani… - Current Research in …, 2022 - Elsevier
The inhaled route is critical for the administration of drugs to treat patients suffering from
COPD, but there is still an unmet need for new and innovative inhalers to address some …
COPD, but there is still an unmet need for new and innovative inhalers to address some …
M2 muscarinic receptor-dependent contractions of airway smooth muscle are inhibited by activation of β-adrenoceptors
T Alkawadri, PY Wong, Z Fong, FT Lundy… - Function, 2022 - academic.oup.com
Abstract Beta-adrenoceptor (β-AR) agonists inhibit cholinergic contractions of airway smooth
muscle (ASM), but the underlying mechanisms are unclear. ASM cells express M3 and M2 …
muscle (ASM), but the underlying mechanisms are unclear. ASM cells express M3 and M2 …
Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease …
F Rancati, ID Linney, A Rizzi, M Delcanale… - Bioorganic & Medicinal …, 2021 - Elsevier
The targeting of both the muscarinic and β-adrenergic pathways is a well validated
therapeutic approach for the treatment of chronic obstructive pulmonary disease (COPD). In …
therapeutic approach for the treatment of chronic obstructive pulmonary disease (COPD). In …
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update
MG Matera, B Rinaldi, L Calzetta… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Strong scientific evidence and large experience support the use of β2-agonists
for the symptomatic alleviation of COPD. Therefore, there is considerable effort in …
for the symptomatic alleviation of COPD. Therefore, there is considerable effort in …